Joshua Fitch, Senior Editor

From strong data for JNJ-2113 to a deep dive into climate change and pediatric health care, get caught up with our weekly review article.

Do you know the details from the American Academy of Pediatrics' 2024 CCHD updated screening recommendations?

“Data from the Phase 3 ICONIC LEAD subgroup analysis demonstrate impressive efficacy rates, showing the promise of this novel therapeutic option," said Lawrence Eichenfield, MD.

The federal agency greenlit nivolumab with ipilimumab for treating MSI-H/dMMR colorectal cancer in adults and children 12 years and up.

Ambulatory blood pressure monitoring at point-of-care shows high feasibility for pediatric hypertension diagnosis in clinical practice.

If approved, the expanded indication would include children and adolescents aged 6 to 17 years who weigh 99 lbs (45 kg) or more.

In the phase 3 TRANSCEND trial, setmelanotide met the primary endpoint of a statistically significant and clinically meaningful BMI reduction compared to placebo.

A newly published Swedish study supports other research that suggests screen time displaces sleep in multiple ways.

View our Q1 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Fathers who took 2 or more weeks of leave after the birth of their infant were more likely to report longer breastfeeding duration.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from March 2025.

Submission is based on 3 clinical trials, including data from the ApproaCH Trial among children with achondroplasia.

Jay T. Rubinstein, MD, PhD, emphasized that children with hearing loss should receive genetic testing, as the investigational DB-OTO gene therapy demonstrated positive results.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Fitusiran is administered subcutaneously starting once every 2 months for patients aged 12 years and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors.

A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments.

Mesoblast's remestemcel-L (Ryoncil) was approved by the FDA on December 18, 2024 to treat SR-aGVHD in patients 2 months and older. Now, it is available for purchase.

Peter Lio, MD, offers thoughts on recent atopic dermatitis data reported for lebrikizumab.

Diazoxide choline has been granted breakthrough, fast track, and orphan drug designations in the United States.

In this Q+A interview, Craig McDonald, MD, discusses the interim, 90-day data from the phase 1/2 INSPIRE DUCHENNE trial, evaluating SGT-003, a gene therapy candidate for DMD.

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Pediatric cancer survivors can be vulnerable to cardiovascular disease in the short- or long-term with increased recognition of cardiotoxic cancer treatments, as 5-year survival rates for children are greater than 85%.

Walker and Harris emphasize the importance of early hearing loss detection, screening, and intervention to support optimal child development.

Take your best guess and try to diagnose this 9-year-old girl's linear eruption on the back of her left thigh and leg. Stay tuned for the full case presentation and correct diagnosis!

Peter S. Jensen, MD, discusses the risks and benefits of social media use by children, emphasizing the need for parental oversight and national guidelines.

Results were from the phase 3 STEER study among a broad population of patients with SMA aged 2 to under 18 years.

The federal agencies are encouraging companies to develop new infant formulas and clarify opportunities to inform consumers about formula ingredients.

Danielle Van Damme, DNP, CPNP-AC, discussed key updates from the 2024 IDSA guideline on diagnosing complicated intra-abdominal infections, emphasizing ultrasound as the preferred imaging modality.